Beam Therapeutics (BEAM) Non-Current Deffered Revenue: 2020-2025

Historic Non-Current Deffered Revenue for Beam Therapeutics (BEAM) over the last 5 years, with Sep 2025 value amounting to $10.2 million.

  • Beam Therapeutics' Non-Current Deffered Revenue fell 82.43% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year decrease of 82.43%. This contributed to the annual value of $33.2 million for FY2024, which is 69.77% down from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Non-Current Deffered Revenue is $10.2 million, which was down 50.00% from $20.3 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Non-Current Deffered Revenue peaked at $262.3 million during Q4 2021, and registered a low of $10.2 million during Q3 2025.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $75.5 million (2024), whereas its average is $82.6 million.
  • As far as peak fluctuations go, Beam Therapeutics' Non-Current Deffered Revenue spiked by 66,474.37% in 2021, and later plummeted by 82.43% in 2025.
  • Over the past 5 years, Beam Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $262.3 million in 2021, then declined by 22.92% to $202.2 million in 2022, then tumbled by 45.65% to $109.9 million in 2023, then crashed by 69.77% to $33.2 million in 2024, then crashed by 82.43% to $10.2 million in 2025.
  • Its last three reported values are $10.2 million in Q3 2025, $20.3 million for Q2 2025, and $49.4 million during Q1 2025.